论文部分内容阅读
目的观察吡格列酮对早期2型糖尿病肾病(DN)患者血CRP、Ⅳ型胶原(CIV)、尿微量蛋白排泄率(UAER)的影响。方法 60例早期2型DN患者在原有药物治疗基础上随机分为吡格列酮组及安慰剂组,进行6个月的临床观察,分别比较治疗前后各指标的变化。结果吡格列酮治疗6个月患者CRP、CIV、UAER与本组治疗前比较出现显著下降,差异有统计学意义(P<0.01)。结论早期2型DN患者应用吡格列酮治疗可降低CIV、CRP及UAER的水平,延缓DN的发展。
Objective To observe the effect of pioglitazone on blood levels of CRP, CIV and UAER in patients with early type 2 diabetic nephropathy (DN). Methods Sixty patients with early type 2 DN were randomly divided into pioglitazone group and placebo group on the basis of the original drug treatment. The patients were followed up for 6 months. The changes of each index before and after treatment were compared. Results The levels of CRP, CIV and UAER in patients treated with pioglitazone for 6 months were significantly lower than those before treatment (P <0.01). Conclusions The use of pioglitazone in patients with early type 2 DN can reduce the levels of CIV, CRP and UAER and delay the development of DN.